Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.77 |
| ▸ | SHBG | P04278 | 1/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31511910 | 1.00 | ESR1 (0.77) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL30503014 | 0.87 | ESR1 (1.00) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL312243 | 0.87 | ESR1 (1.00) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL9578017 | 0.83 | CYP19A1 (0.67) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL31511905 | 0.83 | CYP19A1 (0.67) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL14855982 | 0.83 | ESR1 (0.72) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL9730612 | 0.82 | ESR1 (0.71) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL31511913 | 0.82 | SMN1; SMN2 (0.70) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL1245832 | 0.82 | MEN1 (0.70) | ESR1SHBGESR2LMNAMAPT | |
| SCHEMBL29535974 | 0.82 | MEN1 (0.70) | ESR1SHBGESR2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023278394-A1 | POLYCATIONIC SALTS OF PHENOLIC COMPOUNDS AND USES THEREOF | FIRMENICH INCORPORATED (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-1743881-B1 | Phenyl-benzyl-ketones | RUANE MICHAEL (AU) | 2010-12-22 | — | — | EP | disclosed |
| US-20100273891-A1 | ISOFLAVONE METABOLITES | Ruane, Michael (AU) | 2010-10-28 | — | — | US | disclosed |
| US-7799955-B2 | Isoflavone metabolites | Ruane, Michael (AU) | 2010-09-21 | — | — | US | disclosed |
| US-20090209655-A1 | ISOFLAVONE METABOLITES | G. J. CONSULTANTS PTY. LTD. (AU) | 2009-08-20 | — | — | US | disclosed |
| US-20080125481-A1 | ISOFLAVONE METABOLITES | JOANNOU GEORGE EUSTACE | 2008-05-29 | — | — | US | disclosed |
| EP-1743881-A1 | Phenyl-benzyl-ketones | G.J. Consultants Pty Ltd (AU) | 2007-01-17 | — | — | EP | disclosed |
| EP-1189897-B1 | ISOFLAVONE METABOLITES | G J CONSULTANTS PTY LTD (AU) | 2006-10-18 | — | — | EP | disclosed |
| US-7056952-B1 | for example, 3'-hydroxy-dihydrodaidzein, 5-hydroxy-O-demethylangolesin; for treating hormone dependent conditions and other diseases and disorders; anticarcinogenic agents | G.J. CONSULTANTS PTY. LTD. (AU) | 2006-06-06 | — | — | US | disclosed |
| US-20050222248-A1 | Isoflavone metabolites | JOANNOU GEORGE E | 2005-10-06 | — | — | US | disclosed |
| EP-1189897-A1 | ISOFLAVONE METABOLITES | G.J. Consultants Pty Ltd (AU) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000066576-A1 | ISOFLAVONE METABOLITES | G.J. CONSULTANTS PTY LTD (AU) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222248-A1 | Isoflavone metabolites | CYP19A1, ESR1, CYP21A2 | ESR1 2/4885SHBG 8/4885ESR2 15/4885 |
| US-20100273891-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | ESR1 2/4885SHBG 8/4885ESR2 10/4885 |
| US-20090209655-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | ESR1 2/4885SHBG 8/4885ESR2 10/4885 |
| US-20080125481-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | ESR1 2/4885SHBG 8/4885ESR2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.